2025年3月11日 · STK11 loss mediates mTORC activation, GLUT1 up-regulation and increased glycolysis. This metabolic reprogramming might represent a therapeutic vulnerability targetable with mTORC1/2...

Presence of mutations in TSC1, TSC2, NF1, NF2 or STK11 genes was assessed using targeted-next generation sequencing (NGS). All eligible patients were treated with everolimus at an initial dose of 10 mg orally once daily in cycles of 28 days. The primary endpoint of this study was overall response rate (ORR).

We present three patients with STK11‐mutated tumors and discuss the proposed mechanisms by which germline and somatic alterations in STK11 promote carcinogenesis, potential approaches for therapeutic targeting, and the new data on resistance to immune checkpoint inhibitors.

The present results suggest that genetic variants of the STK11, PRKAA1, and TSC1 genes could be used as prognostic biomarkers for patients with surgically resected colorectal cancer.

1 (STK11) gene mutations are closely related to PD-1/PD-L1 ICIs. Studies have found that STK11 mutations are related to reduced immune cell i. filtration, low PD-L1 expression and poor response to PD-L1 inhibition. This article reviews the research progress of the cor.

STK11, also known as LKB1, activates mTOR through activation of AMPK and phosphorylation of TSC2, whereas NF1 prevents the downstream activation of the mTOR pathway by terminating the active state of RAS proteins (4,5). Mutations in TSC1, TSC2, STK11 and NF1 genes can lead to mTOR pathway dysregulation and promote tumor cell growth .

2014年4月28日 · The present results suggest that genetic variants of the STK11, PRKAA1, and TSC1 genes could be used as prognostic biomarkers for patients with surgically resected colorectal cancer. Assuming an association between cancer and metabolism, oncogene-directed metabolic reprogramming in cancer has revealed new target strategies.

Deletion of the genes for Tuberous Sclerosis 1 (Tsc1) or Tsc2, regulators of mTORC1 that are downstream of LKB1 signaling, in the oviductal and uterine stroma phenocopies some of the defects observed in Lkb1 mutant mice, confirming that dysregulated mTORC1 activation in the Lkb1-deleted stroma contributes to the phenotype.

2022年1月29日 · STK11 mutation recently have become a biomarker and potential target of interest, especially for patients with lung cancer. Recent trials explore drugs like bemcentinib, everolimus, talazoparib, and others for potential approaches to targeting these mutations.

2012年7月15日 · STK11基因（也称LKB1基因）位于染色体19p13.3，为一种抑癌基因，编码一种丝苏氨酸蛋白激酶，在体内广泛表达，只有与STRAD及MO25结合形成一种完整的复合物才能发挥正常的生物学效应，涉及细胞代谢、细胞凋亡和DNA损伤响应。 STK11蛋白激酶的第84位形成了终止密码子且在第354位出现氨基酸的置换，这类突变导致其蛋白功能的改变有待深入研究。 非小细胞肺癌中含有STK11频发性体细胞突变，导致STK11蛋白的失活，促进肺癌发生、发展和转 …